$LYEL insider trading
Over the last 12 months, Lyell Immunopharma insiders reported 1 buy totaling $12.5M and 28 sales totaling $608K across SEC Form 4 filings. 7% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $12.5M 1 event
- Sold · 12m
- $608K 28 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 7% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Aguirre Jarrad MattieuChief Medical Officer · O | ▼ Sale | 422 | $8.63 | $4K | -2.1% | — |
| Sep 10, 2026 | Shook DavidChief Medical Officer · O | ▼ Sale | 500 | $12.7 | $6K | -2.4% | — |
| Aug 21, 2026 | Seely LynnPresident and CEO · O·D | ▼ Sale | 9,589 | $15.54 | $149K | -13% | — |
| Aug 21, 2026 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 989 | $15.54 | $15K | -5.6% | — |
| Aug 21, 2026 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 1,457 | $15.54 | $23K | -8.2% | — |
| Aug 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller · O | ▼ Sale | 621 | $14.34 | $9K | -4% | — |
| Aug 10, 2026 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 131 | $14.34 | $2K | -0.7% | — |
| Aug 10, 2026 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 89 | $14.34 | $1K | -0.5% | — |
| Aug 10, 2026 | Seely LynnPresident and CEO · O·D | ▼ Sale | 390 | $14.34 | $6K | -0.5% | — |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% | ▼ Sale | 10 | $13.7 | $137 | — | plan |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% | ▼ Sale | 10 | $13.73 | $137 | — | plan |
| Jun 10, 2026 | Shook DavidChief Medical Officer · O | ▼ Sale | 1,977 | $12.64 | $25K | -8.6% | — |
| May 11, 2026 | Seely LynnPresident and CEO · O·D | ▼ Sale | 388 | $18.91 | $7K | -0.5% | late |
| May 11, 2026 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 130 | $18.92 | $2K | -0.7% | late |
| May 11, 2026 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 89 | $18.92 | $2K | -0.5% | late |
| May 11, 2026 | Bulis Veronica SanchezVP, Corporate Controller · O | ▼ Sale | 217 | $18.91 | $4K | -1.4% | late |
| Mar 6, 2026 | ARCH Venture Partners IX, LLC10% | ▲ Buy | 488,090 | $25.61 | $12.5M | +52% | co-filed copy · indirect |
| Mar 6, 2026 | ARCH Venture Fund XIII, L.P.10% | ▲ Buy | 488,090 | $25.61 | $12.5M | +52% | indirect |
| Feb 11, 2026 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 1,671 | $23.39 | $39K | -9% | — |
| Feb 11, 2026 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 1,236 | $23.39 | $29K | -6.5% | — |
| Feb 11, 2026 | Seely LynnPresident and CEO · O·D | ▼ Sale | 7,455 | $23.39 | $174K | -9.1% | — |
| Feb 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller · O | ▼ Sale | 254 | $23.12 | $6K | -1.6% | — |
| Feb 10, 2026 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 147 | $23.12 | $3K | -0.8% | — |
| Feb 10, 2026 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 109 | $23.12 | $3K | -0.6% | — |
| Feb 10, 2026 | Seely LynnPresident and CEO · O·D | ▼ Sale | 438 | $23.12 | $10K | -0.5% | — |
| Dec 30, 2025 | Bulis Veronica SanchezVP, Corporate Controller · O | ▼ Sale | 2,072 | $35.8 | $74K | -22.5% | late · 2 tranches |
| Nov 10, 2025 | Bulis Veronica SanchezVP, Corporate Controller · O | ▼ Sale | 239 | $16.1 | $4K | -2.5% | — |
| Nov 10, 2025 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 138 | $16.16 | $2K | -0.9% | — |
| Nov 10, 2025 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 95 | $16.12 | $2K | -0.6% | — |
| Nov 10, 2025 | Seely LynnPresident and CEO · O·D | ▼ Sale | 412 | $16.11 | $7K | -0.6% | — |
| Aug 21, 2025 | Seely LynnPresident and CEO · O·D | ▼ Sale | 7,257 | $10.54 | $77K | -9.7% | — |
| Aug 21, 2025 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 1,004 | $10.54 | $11K | -6% | — |
| Aug 21, 2025 | Newton Charles W.Chief Financial Officer · O | ▼ Sale | 1,453 | $10.54 | $15K | -8.7% | — |
| Aug 21, 2025 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 1,453 | $10.54 | $15K | -8.6% | — |
| Aug 12, 2025 | Seely LynnPresident and CEO · O·D | ▼ Sale | 797 | $10.43 | $8K | -2.2% | 2 tranches |
| Aug 12, 2025 | Hill Stephen J.Chief Operating Officer · O | ▼ Sale | 185 | $10.43 | $2K | -2% | 2 tranches |
| Aug 12, 2025 | Lee Gary K.Chief Scientific Officer · O | ▼ Sale | 267 | $10.43 | $3K | -2.9% | 2 tranches |
| Aug 12, 2025 | Newton Charles W.Chief Financial Officer · O | ▼ Sale | 267 | $10.43 | $3K | -3% | 2 tranches |
Every $LYEL filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Lyell Immunopharma filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $LYEL feed.